Challenges Ahead For Assam’s CSIR-NEIST Team In Releasing India’s First Patented Cost Effective CQDs For Cancer Diagnosis?

Coal's Life Saving Signs

Now what is CQDs and how it helps in effective detection of cancer cell? The real CQDs scenario in India is that it is a chemical composition of carbon based nanomaterials which are imported by health and diagnostic centers at a price Rs. 2000 per ml to diagnose cancer cell.

Now ml percentage is too small to procure at Rs. 2000 but that is what happening in affluent Health diagnostic centers on national level according to the Jorhat scientist from Polymer Petroleum and Coal Chemistry group of the Council of Scientific & Industrial Research – North East Institute of Science and Technology (CSIR-NEIST).

Interestingly Jorhat’s NIEST scientist team have found a best alternative CQDs nanomaterial or carbon dots result to be applied in bio-imaging diagnostic tools for chemical sensing and opto electronic to detect cancer cell in better quality image.

The striking part in making this effective technology avail in the market for sales is that it will lower the charges of cancer cell diagnosis in all healthcare diagnostic centers, preventing greater burn on patient’s pocket as according to the team head of this patented CQDs innovation Binoy Kumar Saikia who stated, “Following expensive US and Japan based CQDs diagnostic technology provider whose rate is Rs. 2000 per ml they have a better alternative. If any multinational Pharma company helps them to launch their cheap but environment friendly, intoxic or low toxic, good conductivity and high stability chemical composition derived from low rate sulphar content coal @ Rs. 50 per ml then they are ready to sell.”

Cell Bio-ImagingTechno For Cancer Detection

The hurdle after the biggest innovation of CQDs blue fluroscent carbon nanomaterials from sulphuric coal that is to be availed just at one twentieth price of the imported ones, Binoy Saikia revealed, “There are certain complex Supreme Court jurisdiction in availing medical related materials in the market which CSIR-NEIST, Jorhat has to muscle up and simultaneously work out with approachable investors interested to launch their cancer cell technology in the market. It will be a long process if luck do not favors. Else they have to rely on international agents to fetch for best price for their innovation but NEIST team would definitely look forward to get their patent recognized first in Indian market.”

On previous case studies it has been revealed that the Indian Supreme Court’s refused to process Swiss Pharma based patented cancer drug brand Gleevec by Novartis giant Pharmaceutical company due to extensive price labeling that goes against the norms of greater penetration in the market

Next is a Generic Drug Manufacturing Indian company Natco Pharma Ltd that received nod from the Supreme Court to sell their patented Nexavar branded anti-cancer drug from Bayer Healthcare of Germany.

But later got jinxed when Natco filed an application for CL under Patent Act section 84 (5) (iv) against non-profit Third World Network, Bayer Pharma for the grant of Compulsory license to have the right to manufacture for greater accessibility of the product at an affordable price due to extensive demand.

To which Bayer multinational Pharma company had opposed the CL application against it for implementing extensive price in marketing Sorafenib cancer drug due to extensive research and development cost. Bayer justifies its stance by highlighting that It has legal right to determine the price.

The jurisdiction of SC has to go against Byer Pharma company later after its successful launch of the imported product with unbelievable fetch of price of Rs. 2 Lakhs  to help extend patient’s longevity to 4-5 years in kidney cancer victims while liver patients 6-8 months.

Natco Pharma though being privileged to be the first ever company to be licensed to produce their Sorafenib drug labeled with new Nexavar Brand name to counteract the deadly disease without harsh surgery method had to make a choice to lower the rate at Rs. 8880 per patient on monthly basis for greater penetration in the market.

According to the Child’s, Director Of Policy And Advocacy at the international non-profit, Medicines Sans Frontiers (MSF) this jurisdiction from the Supreme Court justifies Patient support groups and public health activists effort to avail public right to access innovative and effective health products at a standard affordable price. Jorhat NEIST team needs sound marketing strategy to popularize their product and greater penetration in Indian drug market.

NEIC Business Analytic Report: SUMI BORA
Top Image: NEIC